Skip to main content
    I

    INmune Bio Inc (INMB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.95
    -0.10 (-9.87%)

    Market Cap: $32.51M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    INmune Bio Inc (INMB) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    INmune Bio reported revenue of $50.00K for the fiscal year ended Dec 31, 2025, up 257.1% from the year before. That year, net income was -$45.93M with a net margin of -91866.0%, operating cash flow was -$22.58M and free cash flow was -$23.62M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$4.72M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue grew from $11.00K, a compound annual rate of 35.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$50.00K+257.1%100.0%-94766.0%-91866.0%
    Dec 2024$14.00K-91.0%100.0%-304535.7%-300585.7%
    Dec 2023$155.00K-58.6%100.0%-19187.7%-19360.0%
    Dec 2022$374.00K+106.6%100.0%-6938.8%-7299.2%
    Dec 2021$181.00K+1545.5%100.0%-16106.6%-16762.4%
    Dec 2020$11.00KN/A100.0%-111163.6%-109990.9%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$50.00K$14.00K$155.00K$374.00K$181.00K$11.00K$0$0$0$0
    Gross profit$50.00K$14.00K$155.00K$374.00K$181.00K$11.00K$0$0$0$0
    Research and development$20.66M$33.17M$20.27M$17.07M$20.54M$5.92M$3.28M$3.35M$435.36K$101.50K
    Operating income-$47.38M-$42.63M-$29.74M-$25.95M-$29.15M-$12.23M-$7.76M-$12.44M-$981.48K-$227.00K
    Net income-$45.93M-$42.08M-$30.01M-$27.30M-$30.34M-$12.10M-$7.68M-$12.44M-$831.49K-$277.00K
    EBITDA-$47.30M-$42.56MN/AN/A-$29.03M-$12.10M-$7.68M-$12.44MN/A-$50.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$50.00K$0$0$0$14.00K$28.00K
    Gross profit$0$0$0-$56.00K$0$0$50.00KN/A$0$0$14.00K$28.00K
    Operating income-$5.01M-$1.48M-$5.81M-$5.47M-$7.43M-$24.57M-$9.90M-$9.47M-$12.29M-$9.87M-$11.02M-$8.38M
    Net income-$4.72M-$1.27M-$5.41M-$5.26M-$6.47M-$24.46M-$9.74M-$9.22M-$12.09M-$9.75M-$11.03M-$8.41M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $623.00K by $24.13M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$32.35M$39.56M$57.00M$81.80M$99.94M$40.66M$24.47M$17.36M$18.41M$451.61K
    Current assets$29.89M$22.66M$39.94M$64.67M$82.61M$23.99M$7.76M$849.34K$1.90M$451.61K
    Cash and equivalents$24.75M$20.92M$35.85M$52.15M$74.81M$21.97M$7.00M$186.20K$1.37M$141.66K
    Total liabilities$8.83M$7.46M$18.86M$21.69M$19.72M$1.90M$860.54K$823.77K$309.72K$600.81K
    Short-term debt$623.00K$140.00K$9.92M$5.00M$0$34.00K$8.29KN/AN/A$350.00K
    Long-term debtN/AN/AN/A$9.70M$14.46M$0N/AN/AN/AN/A
    Shareholder equity$23.52M$32.10M$37.34M$60.10M$80.22M$38.75M$23.61M$16.54M$18.10M-$149.20K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$21.51M$26.84M$25.82M$32.35M$33.36M$37.68M$37.80M$39.56M$52.78M$52.45M$46.83M$57.00M
    Total liabilities$3.44M$6.48M$6.19M$8.83M$7.98M$8.82M$8.13M$7.46M$14.11M$15.37M$17.81M$18.86M
    Cash and equivalents$16.33M$18.41M$21.36M$24.75M$27.73M$33.37M$19.34M$20.92M$33.55M$31.07M$26.00M$35.85M
    Shareholder equity$18.07M$20.36M$19.62M$23.52M$25.38M$28.87M$29.67M$32.10M$38.67M$36.28M$28.22M$38.14M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$22.58M-$33.36M-$11.98M-$22.69M-$28.50M-$8.94M-$5.38M-$2.06M-$761.83K-$317.38K
    Capital expenditures$1.04M$0$0$0$15.00M$4$0$0$100.00K$0
    Free cash flow-$23.62M-$33.36M-$11.98M-$22.69M-$43.50M-$8.94M-$5.38M-$2.06M-$861.83K-$317.38K
    Investing cash flow-$1.04M$0$0$0-$15.00M$0$0$0-$100.00K-$100.00K
    Financing cash flow$27.61M$18.21M-$4.22M$729.00K$96.36M$23.89M$12.21M$900.00K$2.06M$450.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.39M-$3.17M-$3.40M-$2.94M-$5.44M-$7.38M-$6.82M-$11.01M-$6.99M-$7.89M-$7.48M-$3.40M
    Capital expendituresN/AN/A$0$143.00K$193.00K$706.00K$0$0$0$0$0$0
    Free cash flowN/AN/A-$3.40M-$3.09M-$5.63M-$8.08M-$6.82M-$11.01M-$6.99M-$7.89M-$7.48M-$3.40M
    Last 12 quarters

    Frequently Asked Questions About INMB

    What is INmune Bio's annual revenue?

    INmune Bio reported revenue of $50.00K for the fiscal year ended Dec 31, 2025.

    How fast is INmune Bio's revenue growing?

    Revenue was up 257.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -48.9%.

    Is INmune Bio profitable?

    No. INmune Bio reported net income of -$45.93M for the fiscal year ended Dec 31, 2025, with a net margin of -91866.0%.

    How much free cash flow does INMB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$22.58M minus capital expenditures of $1.04M produced free cash flow of -$23.62M.

    How much debt does INmune Bio have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $623.00K and cash and equivalents of $24.75M.